Comprehensive characterization of the tumor microenvironment for assessing immunotherapy outcome in patients with head and neck squamous cell carcinoma

被引:0
作者
Zhang, Jian [1 ,2 ]
Zhong, Xi [3 ]
Jiang, Huali [4 ]
Jiang, Hualong [5 ]
Xie, Tao [1 ,2 ]
Tian, Yunhong [1 ,2 ]
Li, Rong [1 ,2 ]
Wang, Baiyao [1 ,2 ]
Zhang, Jiexia [6 ]
Yuan, Yawei [1 ,2 ]
机构
[1] Guangzhou Med Univ, Affiliated Canc Hosp & Inst, Dept Radiat Oncol, Guangzhou 510095, Peoples R China
[2] Guangzhou Inst Resp Dis, State Key Lab Resp Dis, Guangzhou 510095, Peoples R China
[3] Guangzhou Med Univ, Radiat Dept, Affiliated Canc Hosp & Inst, Guangzhou 510095, Peoples R China
[4] Sun Yat Sen Univ, Dept Cardiovascularol, Tungwah Hosp, Dongguan 523000, Peoples R China
[5] Sun Yat Sen Univ, Dept Urol, Tungwah Hosp, Dongguan 523000, Peoples R China
[6] Guangzhou Med Univ, State Key Lab Resp Dis, Natl Clin Res Ctr Resp Dis, Guangzhou Inst Resp Hlth,Affiliated Hosp 1, Guangzhou 510120, Peoples R China
来源
AGING-US | 2020年 / 12卷 / 22期
关键词
head and neck squamous cell carcinoma; tumor microenvironment; immunotherapy; single nucleotide variants; copy number variations; PD-1; BLOCKADE; MUTATIONAL PROCESSES; BREAST-CANCER; COPY-NUMBER; EXPRESSION; RECURRENT; PEMBROLIZUMAB; LANDSCAPE; NIVOLUMAB; SIGNATURES;
D O I
暂无
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
The tumor microenvironment (TME) constitutes a complex milieu of cells and cytokines that maintain equilibrium between tumor progression and prognosis. However, comprehensive analysis of the TME and its clinical significance in head and neck squamous cell carcinoma (HNSCC) remains to be unreported. In this study, based on large-scale RNA sequencing data pertaining to single nucleotide variants (SNVs) and copy number variations (CNVs) in HNSCC patients from The Cancer Genome Atlas database, we analysed subpopulations of infiltrating immune cells and evaluated the role of TME infiltration pattern (TME score) in assessing immunotherapy outcome. TME signature genes involved in several inflammation and immunity signalling pathways were observed in the TME score subtype, which were considered immunosuppressive and potentially responsible for significantly worse prognosis. In comparison with SNVand CNV-mediated tumor mutation burden, TME score can significantly differentiate between highand low-risk HNSCC and predict immunotherapy outcome. Our data provide clarity on the comprehensive landscape of interactions between clinical characteristics of HNSCC and tumor-infiltrating immune cells. TME score seems to be a useful biomarker that can predict immunotherapy outcome in HNSCC patients.
引用
收藏
页码:22509 / 22526
页数:18
相关论文
共 50 条
  • [31] Immunotherapy in recurrent and or metastatic squamous cell carcinoma of the head and neck
    Saada-Bouzid, Esma
    Peyrade, Frederic
    Guigay, Joel
    CURRENT OPINION IN ONCOLOGY, 2019, 31 (03) : 146 - 151
  • [32] Novel immunotherapy combinations in head and neck squamous cell carcinoma
    Kankotia, Shyam
    Park, Soyun
    Thomas, Jacob
    CURRENT OPINION IN ONCOLOGY, 2025, 37 (03) : 209 - 217
  • [33] Salvage chemotherapy after progression on immunotherapy in recurrent/metastatic squamous cell head and neck carcinoma
    Llop, Sandra
    Plana, Maria
    Tous, Sara
    Ferrando-Diez, Angelica
    Brenes, Jesus
    Juarez, Marc
    Vidales, Zara
    Vilajosana, Esther
    Linares, Isabel
    Arribas, Lorena
    Duch, Maria
    Fulla, Marta
    Brunet, Aina
    Lozano, Alicia
    Cirauqui, Beatriz
    Mesia, Ricard
    Oliva, Marc
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [34] A 25-gene panel predicting the benefits of immunotherapy in head and neck squamous cell carcinoma
    Huang, Yongsheng
    Liao, Jianwei
    Liang, Faya
    Lin, Peiliang
    Wu, Sangqing
    Ye, Yuchu
    Gao, Ming
    Chen, Renhui
    Zeng, Haicang
    Yin, Xinke
    Jiang, Yuanling
    Ouyang, Nengtai
    Han, Ping
    Huang, Xiaoming
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2022, 110
  • [35] Neoadjuvant Immunotherapy for Head and Neck Squamous Cell Carcinoma: Expecting Its Application in Temporal Bone Squamous Cell Carcinoma
    Shi, Meng-wen
    Huang, Jing
    Sun, Yu
    CURRENT MEDICAL SCIENCE, 2023, 43 (02) : 213 - 222
  • [36] Targeting Angiogenesis in Squamous Cell Carcinoma of the Head and Neck: Opportunities in the Immunotherapy Era
    Saba, Nabil F.
    Vijayvargiya, Pooja
    Vermorken, Jan B.
    Rodrigo, Juan P.
    Willems, Stefan M.
    Zidar, Nina
    de Bree, Remco
    Maekitie, Antti
    Wolf, Greg T.
    Argiris, Athanassios
    Teng, Yong
    Ferlito, Alfio
    CANCERS, 2022, 14 (05)
  • [37] Pyroptosis patterns influence the clinical outcome and immune microenvironment characterization in HPV-positive head and neck squamous cell carcinoma
    Doudou Li
    Dong Ma
    Yuxia Hou
    Infectious Agents and Cancer, 18
  • [38] Characterization of the T-Cell Receptor Repertoire and Immune Microenvironment in Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck
    Saloura, Vassiliki
    Fatima, Aiman
    Zewde, Makda
    Kiyotani, Kazuma
    Brisson, Ryan
    Park, Jae-Hyun
    Ikeda, Yuji
    Vougiouklakis, Theodore
    Bao, Riyue
    Khattri, Arun
    Seiwert, Tanguy
    Cipriani, Nicole
    Lingen, Mark
    Vokes, Everett
    Nakamura, Yusuke
    CLINICAL CANCER RESEARCH, 2017, 23 (16) : 4897 - 4907
  • [39] How Risk Factors Affect Head and Neck Squamous Cell Carcinoma (HNSCC) Tumor Immune Microenvironment (TIME): Their Influence on Immune Escape Mechanisms and Immunotherapy Strategy
    Galizia, Danilo
    Minei, Silvia
    Maldi, Elena
    Chila, Giovanna
    Polidori, Alessio
    Merlano, Marco Carlo
    BIOMEDICINES, 2022, 10 (10)
  • [40] Tumor microenvironment and immune-related therapies of head and neck squamous cell carcinoma
    Qin, Yixiao
    Zheng, Xiwang
    Gao, Wei
    Wang, Binquan
    Wu, Yongyan
    MOLECULAR THERAPY ONCOLYTICS, 2021, 20 : 342 - 351